Literature DB >> 25827173

NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.

Jan Verner1,2, Martin Trbusek1,2, Jana Chovancova2, Zuzana Jaskova2, Mojmir Moulis3, Frantisek Folber1, Roman Halouzka4, Jiri Mayer1,2, Sarka Pospisilova1,2, Michael Doubek1,2.   

Abstract

Xenograft models represent a promising tool to study the pathogenesis of hematological malignancies. To establish a reliable and appropriate in vivo model of aggressive human B-cell leukemia and lymphoma we xenotransplanted four p53-mutated cell lines and one ATM-mutated cell line into immunodeficient NOD/SCID IL2Rγ-null mice. The cell lines MEC-1, SU-DHL-4, JEKO-1, REC-1, and GRANTA-519 were transplanted intraperitoneally or subcutaneously and the engraftment was investigated using immunohistochemistry and flow cytometry. We found significant differences in engraftment efficiency. MEC-1, JEKO-1 and GRANTA-519 cell lines engrafted most efficiently, while SU-DHL-4 cells did not engraft at all. MEC-1 and GRANTA-519 massively infiltrated organs and the whole intraperitoneal cavity showing very aggressive growth. In addition, GRANTA-519 cells massively migrated to the bone marrow regardless of the transplantation route. The MEC-1 and GRANTA-519 cells can be especially recommended for in vivo study of p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma, respectively.

Entities:  

Keywords:  Chronic lymphocytic leukemia; NSG mouse; mantle cell lymphoma; xenograft model

Mesh:

Substances:

Year:  2015        PMID: 25827173     DOI: 10.3109/10428194.2015.1034701

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?

Authors:  Chelsey L Patten; Christine E Cutucache
Journal:  Front Oncol       Date:  2016-12-14       Impact factor: 6.244

2.  Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.

Authors:  Keshu Zhou; Wentao Zhang; Qing Zhang; Ruirui Gui; Huifang Zhao; Xiaofei Chai; Yufu Li; Xudong Wei; Yongping Song
Journal:  Oncotarget       Date:  2017-04-11

3.  Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Authors:  Miroslav Boudny; Jana Zemanova; Prashant Khirsariya; Marek Borsky; Jan Verner; Jana Cerna; Alexandra Oltova; Vaclav Seda; Marek Mraz; Josef Jaros; Zuzana Jaskova; Michaela Spunarova; Yvona Brychtova; Karel Soucek; Stanislav Drapela; Marie Kasparkova; Jiri Mayer; Kamil Paruch; Martin Trbusek
Journal:  Haematologica       Date:  2019-04-11       Impact factor: 9.941

4.  Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.

Authors:  Carlos Cuesta-Mateos; Raquel Juárez-Sánchez; Tamara Mateu-Albero; Javier Loscertales; Wim Mol; Fernando Terrón; Cecilia Muñoz-Calleja
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.